热点:
马里兰州日耳曼敦, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc.(纳斯达克:CUR)是一家根据其神经干细胞技术专门开发中枢神经系统疗法的生物制药公司。该公司公布截至2017年9月30日止三个月和九个月期间的财务业绩。
董事长兼首席执行官Rich Daly评论道,“在取得非常令人鼓舞的临床前数据之后,我们继续评估NSI-189第二期研究的全部数据集,以确定重度抑郁症和包括天使综合症等其它疾病的最佳发展路径。我们预计将在2018年上半年与FDA举行第二期研究后会议之后提供最新企业策略的详情,包括发展和监管计划。”
“我们近期的融资进一步扩大了公司的现金储备,为NSI-189的后续研究和业务经营提供充足的支持。NSI-189最新的临床状况令我们备受鼓舞,我们期待在即将于12月举行的美国神经精神药理学会会议上呈报更多临床数据。”
最近的企业和临床概要及里程碑
于2017年11月6日,我们委任医学博士David Recker为首席医疗官,增强了临床研究团队的实力。Recker在多个治疗领域的药物开发方面积累了超过20年的经验,包括CNS和细胞疗法,并且曾参与临床策略开发的多个方面,包括产品注册和营销支持、临床试验开发和执行、数据诠释、关键意见领袖开发和支持。
Unaudited Condensed Consolidated Balance Sheets | |||||||
September 30, 2017 | December 31, 2016 | ||||||
ASSETS | |||||||
CURRENT ASSETS | |||||||
Cash and cash equivalents | $ | 9,063,710 | $ | 15,194,949 | |||
Short-term investments | 5,000,000 | 5,000,000 | |||||
Trade and other receivables | 37,458 | 10,491 | |||||
Current portion of related party receivable, net of discount | 57,291 | 53,081 | |||||
Prepaid expenses | 548,766 | 646,195 | |||||
Total current assets | 14,707,225 | 20,904,716 | |||||
Property and equipment, net | 196,191 | 269,557 | |||||
Patents, net | 915,457 | 990,153 | |||||
Related party receivable, net of discount and current portion | 356,174 | 424,240 | |||||
Other assets | 13,719 | 15,662 | |||||
Total assets | $ | 16,188,766 | $ | 22,604,328 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
CURRENT LIABILITIES | |||||||
Accounts payable and accrued expenses | $ | 1,476,683 | $ | 2,343,936 | |||
Accrued bonuses | - | 852,963 | |||||
Current portion of long-term debt, net of fees and discount | - | 3,705,787 | |||||
Other current liabilities | 358,044 | 430,738 | |||||
Total current liabilities | 1,834,727 | 7,333,424 | |||||
Derivative liabilities | 2,785,863 | 3,921,917 | |||||
Other long-term liabilities | 3,400 | 18,209 | |||||
Total liabilities | 4,623,990 | 11,273,550 | |||||
STOCKHOLDERS' EQUITY | |||||||
Convertible preferred stock, 7,000,000 shares authorized, $0.01 par value; 1,000,000 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 10,000 | 10,000 | |||||
Common stock, $0.01 par value; 300 million shares authorized, 15,146,027 and 11,032,858 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 151,460 | 110,329 | |||||
Additional paid-in capital | 216,784,493 | 204,239,837 | |||||
Accumulated other comprehensive income | 2,345 | 3,905 | |||||
Accumulated deficit | (205,383,522 | ) | (193,033,293 | ) | |||
Total stockholders' equity | 11,564,776 | 11,330,778 | |||||
Total liabilities and stockholders' equity | $ | 16,188,766 | $ | 22,604,328 |
Neuralstem, Inc. | ||||||||||||||||
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Revenues | $ | 2,500 | $ | 2,500 | $ | 7,500 | $ | 7,500 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development expenses | 1,383,863 | 3,589,793 | 6,871,028 | 9,130,012 | ||||||||||||
General and administrative expenses | 1,206,510 | 1,329,712 | 4,174,583 | 5,862,374 | ||||||||||||
Total operating expenses | 2,590,373 | 4,919,505 | 11,045,611 | 14,992,386 | ||||||||||||
Operating loss | (2,587,873 | ) | (4,917,005 | ) | (11,038,111 | ) | (14,984,886 | ) | ||||||||
Other income (expense): | ||||||||||||||||
Interest income | 18,099 | 17,293 | 52,995 | 41,862 | ||||||||||||
Interest expense | (1,383 | ) | (240,462 | ) | (155,843 | ) | (949,375 | ) | ||||||||
Change in fair value of derivative instruments | 2,679,770 | (538,261 | ) | (403,155 | ) | 219,014 | ||||||||||
Gain on related party settlement | - | 458,608 | - | 458,608 | ||||||||||||
Fees related to issuance of derivative liabilities, warrant inducement and other expenses | (242,396 | ) | (456 | ) | (806,115 | ) | (463,798 | ) | ||||||||
Total other income (expense) | 2,454,090 | (303,278 | ) | (1,312,118 | ) | (693,689 | ) | |||||||||
Net loss | $ | (133,783 | ) | $ | (5,220,283 | ) | $ | (12,350,229 | ) | $ | (15,678,575 | ) | ||||
Net loss per share - basic | $ | (0.01 | ) | $ | (0.59 | ) | $ | (1.00 | ) | $ | (1.96 | ) | ||||
Net loss per share - diluted | $ | (0.18 | ) | $ | (0.59 | ) | $ | (1.00 | ) | $ | (1.96 | ) | ||||
Weighted average common shares outstanding - basic | 14,060,844 | 8,835,045 | 12,380,054 | 8,019,153 | ||||||||||||
Weighted average common shares outstanding - diluted | 14,163,072 | 8,835,045 | 12,380,054 | 8,019,153 | ||||||||||||
Comprehensive loss: | ||||||||||||||||
Net loss | $ | (133,783 | ) | $ | (5,220,283 | ) | $ | (12,350,229 | ) | $ | (15,678,575 | ) | ||||
Foreign currency translation adjustment | (1,005 | ) | 21 | (1,560 | ) | 1,516 | ||||||||||
Comprehensive loss | $ | (134,788 | ) | $ | (5,220,262 | ) | $ | (12,351,789 | ) | $ | (15,677,059 | ) | ||||